Physician profile
Tomasz Andrejuk
NPI 1871524470
$12,671.36
in general payments reported to CMS, 2019-2025
33 companies · $1,933 in 2025
The $1,933 reported for 2025 was more than what 81% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,597 · 2020: $762 · 2021: $1,349 · 2022: $1,706 · 2023: $2,088 · 2024: $1,235 · 2025: $1,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,747 · Travel and Lodging: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,747.05 |
| Travel and Lodging | $509.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,460.35 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Nevro Corp. | $1,675.73 | 2019-2024 | Senza |
| Si-Bone, INC. | $1,427.58 | 2019-2025 | |
| Spr Therapeutics, INC | $1,006.94 | 2023-2025 | Sprint Pns System |
| Scilex Pharmaceuticals INC. | $855.15 | 2019-2024 | Ztlido |
| Relievant Medsystems, INC. | $809.57 | 2021-2022 | |
| Abbott Laboratories | $697.23 | 2019-2023 | Proclaim, Eterna, Cardiomems |
| Nalu Medical, INC. | $624.12 | 2024-2025 | Nalu Neurostimulation System |
| Curonix LLC | $602.23 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Saluda Medical Americas, INC. | $463.31 | 2023-2025 | Evoke, Evoke Scs |
| Collegium Pharmaceutical, INC. | $291.68 | 2019-2021 | |
| Avanos Medical | $263.09 | 2022-2025 | |
| Pfizer INC. | $242.70 | 2019-2023 | |
| Abbvie INC. | $182.19 | 2021-2023 | Ubrelvy |
| Vertex Pharmaceuticals Incorporated | $171.54 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $164.28 | 2019-2022 | |
| Vertos Medical, INC. | $95.92 | 2022 | |
| Medtronic, INC. | $95.38 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Ipsen Biopharmaceuticals, INC | $84.20 | 2024-2025 | Dysport |
| Lilly USA, LLC | $70.54 | 2019-2020 | |
| Globus Medical, INC. | $61.93 | 2025 | Senza |
| Ibsa Pharma INC. | $51.03 | 2021-2024 | Licart, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.51 | 2019 | |
| Grt US Holding, INC. | $42.00 | 2022 | |
| Daiichi Sankyo INC. | $34.24 | 2019 | |
| Fidia Pharma USA INC. | $32.92 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $21.09 | 2022 | |
| Indivior INC. | $17.55 | 2021 | |
| Medtronic USA, INC. | $17.37 | 2019 | |
| Stryker Corporation | $16.01 | 2023 | Multigen 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $15.85 | 2019 | |
| Horizon Therapeutics Plc | $15.75 | 2020 | |
| International Rehabilitative Sciences, INC | $14.38 | 2024 | Rs 4i Plus Sequential Stimulator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomasz Andrejuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.